- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
research use only
Cat.No.S1241
| Related Targets | Akt Wnt/beta-catenin HSP PKC ROCK Microtubule Associated Integrin Bcr-Abl Actin FAK |
|---|---|
| Other Antineoplastic and Immunosuppressive Antibiotics Products | Staurosporine (STS) Cyclosporin A Oligomycin A (MCH 32) Puromycin Dihydrochloride Geldanamycin Honokiol Streptozotocin (STZ) Cephalomannine Sodium Monensin (NSC 343257) 10-Deacetylbaccatin-III |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| HepG2.2.15 | Cell Viability Assay | 0-0.5 μM | 24 h | decreases cell viability dose dependently | 25663769 | |
| HepG2-HBV1.1 | Apoptosis Assay | 0-0.5 μM | 24 h | induces apoptosis dose dependently | 25663769 | |
| HepG2.2.15 | Function Assay | 0.1 μM | 24 h | promotes hepatitis B virus protein expression | 25663769 | |
| HepG2-HBV1.1 | Function Assay | 0.1 μM | 24 h | promotes hepatitis B virus protein expression | 25663769 | |
| HepG2-HBV1.1 | Function Assay | 0.1 μM | 48 h | promotes cell excretion of hepatitis B virus nucleocapsids instead of hepatitis B virus Dane particles | 25663769 | |
| HepG2-HBV1.1 | Growth Inhibition Assay | 0.1 μM | 1-5 d | inhibits the proliferation time dependently | 25663769 | |
| HepG2-HBV1.1 | Growth Inhibition Assay | 0.1 μM | 1-5 d | inhibits the proliferation time dependently | 25663769 | |
| HepG2-HBV1.1 | Growth Inhibition Assay | 0.1 μM | 12-72 h | induces cell cycle arrest at S-phase | 25663769 | |
| HepG2-HBV1.1 | Growth Inhibition Assay | 0.1 μM | 12-72 h | induces cell cycle arrest at S-phase | 25663769 | |
| Raji | Function Assay | 0.5 μM | 72 h | abolishes autophagy | 25446377 | |
| SK-MEL-28 | Function Assay | 30 nM | 6 h | induces G2–M cell-cycle arrest | 25313010 | |
| H157 | Growth Inhibition Assay | IC50=1.03 ± 0.04 miu2M | 25257911 | |||
| Jurkat | Growth Inhibition Assay | 1-3 nM | 48 h | DMSO | decreases viable cell numbers dose dependently | 25156146 |
| CEM | Growth Inhibition Assay | 1-3 nM | 48 h | DMSO | decreases viable cell numbers dose dependently | 25156146 |
| P12 | Growth Inhibition Assay | 1-3 nM | 48 h | DMSO | decreases viable cell numbers dose dependently | 25156146 |
| KB | Growth Inhibition Assay | IC50=0.0049 ± 0.0001 μM | 25058526 | |||
| KBv200 (ABCB1) | Growth Inhibition Assay | IC50=0.3462 ± 0.0066 μM | 25058526 | |||
| SUDHL6 | Growth Inhibition Assay | 1 μM | 48/72 h | inhibits cell viability significantly | 24961604 | |
| SUDHL6 | Function Assay | 1 μM | 72 h | induces significant apoptotic morphology changes cotrested with BCL11A siRNA | 24961604 | |
| HCT-116 | Growth Inhibition Assay | GI50=5 nM | 24927857 | |||
| SKNBe2C | Growth Inhibition Assay | IC50=32.8±4.0 nM | 24921920 | |||
| IGNR91 | Growth Inhibition Assay | IC50=24.3±1.7 nM | 24921920 | |||
| SKNAS | Growth Inhibition Assay | IC50=1.5±0.2 nM | 24921920 | |||
| LAN1 | Growth Inhibition Assay | IC50=2.3±0.2 nM | 24921920 | |||
| SHSY5Y | Growth Inhibition Assay | IC50=8.2±0.6 nM | 24921920 | |||
| A549-WT | Growth Inhibition Assay | IC50=19.437 ± 0.594 nM | 24858827 | |||
| A549-R | Growth Inhibition Assay | IC50=12.178 ± 0.333 nM | 24858827 | |||
| MCF-7-WT | Growth Inhibition Assay | IC50=17.752 ± 0.218 nM | 24858827 | |||
| MCF-7-R | Growth Inhibition Assay | IC50=5.539 ± 0.144 nM | 24858827 | |||
| A549-R | Cytotoxicity Assay | IC50=12.178 ± 0.333 nM | 24858827 | |||
| MCF-7-R | Cytotoxicity Assay | IC50=5.539 ± 0.144 nM | 24858827 | |||
| SW620 | Growth Inhibition Assay | IC50=7.80 ± 0.08 nM | 24726739 | |||
| SW620/AD300 | Growth Inhibition Assay | IC50=909.60 ± 8.91 nM | 24726739 | |||
| HEK293/pcDNA3.1 | Growth Inhibition Assay | IC50=1.45 ± 0.20 nM | 24726739 | |||
| HEK293/ABCC1 | Growth Inhibition Assay | IC50=19.29 ± 2.08 nM | 24726739 | |||
| TCC | Growth Inhibition Assay | 24 h | IC50=70 nM | 24716944 | ||
| TCC | Growth Inhibition Assay | 48 h | IC50=50 nM | 24716944 | ||
| HepG2/ADM | Growth Inhibition Assay | IC50=2.7863±0.2371 μM | 24704556 | |||
| HepG2 | Growth Inhibition Assay | IC50=0.0115±0.0017 μM | 24704556 | |||
| MCF-7/ADR | Growth Inhibition Assay | IC50=4.4826±0.2070 μM | 24704556 | |||
| MCF-7 | Growth Inhibition Assay | IC50=0.0159±0.0062 μM | 24704556 | |||
| A-172 | Growth Inhibition Assay | 0.1 μM | 24/72 h | inhibits cell growth time dependently | 24530235 | |
| U-251MG | Growth Inhibition Assay | 0.1 μM | 24/72 h | inhibits cell growth time dependently | 24530235 | |
| DLD-1 | Function Assay | 100 nM | 48 h | promotes RUNX3 demethylation | 24403453 | |
| CCD18Co | Function Assay | 100 nM | 48 h | promotes RUNX3 demethylation | 24403453 | |
| DLD-1 | Growth Inhibition Assay | 0-1000 nM | 48 h | inhibits cell growth dose dependently | 24403453 | |
| CCD18Co | Growth Inhibition Assay | 0-1000 nM | 48 h | inhibits cell growth dose dependently | 24403453 | |
| HepG2 | Growth Inhibition Assay | 24 h | IC50=52.5 μM | 24341688 | ||
| HEK293/pcDNA3.1 | Growth Inhibition Assay | IC50=0.004±0.0003 μM | 24284783 | |||
| HEK293/MRP1 | Growth Inhibition Assay | IC50=0.055±0.0120 μM | 24284783 | |||
| Ramos | Apoptosis Assay | 2 μM | 48 h | induces 34.6%±1.92% apoptosis | 24256491 | |
| NCI-H1299/pcDNA3 | Cell Viability Assay | 0-20 nM | 96 h | inhibits cell viability dose dependently | 24177012 | |
| H1299/ICAM-3 | Cell Viability Assay | 0-20 nM | 96 h | inhibits cell viability dose dependently | 24177012 | |
| NCI-H1299/pcDNA3 | Function Assay | 1/5/10/20 nM | 96 h | induces cleavage of caspases-3, 8, 9, and PARP | 24177012 | |
| H1299/ICAM-3 | Function Assay | 1/5/10/20 nM | 96 h | induces cleavage of caspases-3, 8, 9, and PARP | 24177012 | |
| W1 | Growth Inhibition Assay | IC50=0.0032 μM | 24140176 | |||
| W1VR | Growth Inhibition Assay | IC50=0.056 μM | 24140176 | |||
| K562 | Growth Inhibition Assay | IC50=0.032 ± 0.001 μM | 24135937 | |||
| K562/ADR | Growth Inhibition Assay | IC50=3.261 ± 0.412 μM | 24135937 | |||
| K562 | Apoptosis Assay | 0.3 μM | 24 h | induces apoptosis significantly | 24135937 | |
| K562/ADR | Apoptosis Assay | 3 μM | 24 h | induces apoptosis | 24135937 | |
| A549 | Growth Inhibition Assay | IC50=0.10 ± 0.03 μM | 23971075 | |||
| K562 | Cell Viability Assay | 3.75–60 nM | 72 h | inhibits cell viability dose dependently | 23877223 | |
| lucena | Cell Viability Assay | 3.75–60 nM | 72 h | no effect | 23877223 | |
| FEPS | Cell Viability Assay | 3.75–60 nM | 72 h | no effect | 23877223 | |
| A2780 | Growth Inhibition Assay | IC50=3.5 mM | 23829203 | |||
| ACHN | Growth Inhibition Assay | IC50<0.1 mM | 23829203 | |||
| U-937 | Growth Inhibition Assay | IC50<34 nM | 23829203 | |||
| Jurkat | Apoptosis Assay | 5 μg/ml | 24 h | induces apoptosis significantly | 23810409 | |
| Jurkat | Growth Inhibition Assay | 5 μg/ml | 24 h | arrest Jurkat cells in G2/M phase | 23810409 | |
| Hep-2 | Growth Inhibition Assay | IC50=0.04±0.01 μM | 23780424 | |||
| Hep-2/v | Growth Inhibition Assay | IC50=1.8±0.20 μM | 23780424 | |||
| SGC-7901 | Growth Inhibition Assay | 0-10 μg/ml | 24/48/72 h | inhibits cell growth in dose and time dependent manner | 23743572 | |
| SGC-7901/VCR | Growth Inhibition Assay | 0-10 μg/ml | 24/48/72 h | inhibits cell growth in dose and time dependent manner | 23743572 | |
| SGC-7901 | Apoptosis Assay | induces apoptosis significantly | 23743572 | |||
| SGC-7901/VCR | Apoptosis Assay | induces apoptosis significantly | 23743572 | |||
| KB-3-1 | Growth Inhibition Assay | IC50=1.66 ± 0.162 μM | 23673445 | |||
| KB-C2 | Growth Inhibition Assay | IC50=202.56 ± 42.481 μM | 23673445 | |||
| KB-3-1 | Growth Inhibition Assay | IC50=1.26 ± 0.027 μM | 23673445 | |||
| KB-V1 | Growth Inhibition Assay | IC50=208.85 ± 20.4 μM | 23673445 | |||
| HEK293/pcDNA3.1 | Growth Inhibition Assay | IC50=24.1 ± 0.204 μM | 23673445 | |||
| HEK293/ABCB1 | Growth Inhibition Assay | IC50=3512.8 ± 378.391 μM | 23673445 | |||
| A549/EGFP | Growth Inhibition Assay | 0.01-1000 μM | IC50=86.7 ± 29.1 μM | 23634282 | ||
| A549/Slug | Growth Inhibition Assay | 0.01-1000 μM | IC50=9.7 ± 3.1 μM | 23634282 | ||
| JFCR39 | Growth Inhibition Assay | 1 µM | 24 h | DMSO | markedly increases the number of G2/M phase cells | 23598276 |
| A549 | Function Assay | 100 nM | 16 h | DMSO | leads to a loss of microtubules | 23598276 |
| SGC7901 | Growth Inhibition Assay | IC50=1.26 ± 0.11 μg/ml | 23564482 | |||
| SGC7901/LV-NC | Growth Inhibition Assay | IC50=1.77 ± 0.16 μg/ml | 23564482 | |||
| SGC7901/LV-SGO1 | Growth Inhibition Assay | IC50=4.36 ± 0.37 μg/ml | 23564482 | |||
| SGC7901/VCR | Growth Inhibition Assay | IC53=20.53 ± 1.96 μg/ml | 23564482 | |||
| SGC7901/VCR-NC | Growth Inhibition Assay | IC50=19.86 ± 2.01 μg/ml | 23564482 | |||
| SGC7901/VCR-si-SGO1 | Growth Inhibition Assay | IC50=6.18 ± 1.03 μg/ml | 23564482 | |||
| SGC7901/ADR | Growth Inhibition Assay | IC50=7.85 ± 0.64 μg/ml | 23564482 | |||
| SGC7901/ADR-NC | Growth Inhibition Assay | IC50=8.93 ± 0.68 μg/ml | 23564482 | |||
| SGC7901/ADR-si-SGO1 | Growth Inhibition Assay | IC50=3.46 ± 0.29 μg/ml | 23564482 | |||
| SH-SY5Y | Growth Inhibition Assay | 0.001-10 μM | 24 h | IC50=0.113±0.012 μM | 23129065 | |
| SH-SY5Y | Growth Inhibition Assay | 0.001-10 μM | 48 h | IC50=0.078±0.009 μM | 23129065 | |
| SH-SY5Y | Growth Inhibition Assay | 0.001-10 μM | 72 h | IC50=0.051±0.008 μM | 23129065 | |
| SH-SY5Y | Apoptosis Assay | 0.1 μM | 0-24 h | induces apoptosis of SH-SY5Y cells following cell cycle arrest at the G2/M phase | 23129065 | |
| SH-SY5Y | Apoptosis Assay | 0.1 μM | 0-24 h | induces mitotic arrest | 23129065 | |
| LNCAP | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay, IC50 = 0.0029 μM. | 20732809 | ||
| LNCAP | Cytotoxicity assay | 72 hrs | Cytotoxicity against human LNCAP cells after 72 hrs by alamar blue assay, IC50 = 0.0061 μM. | 23215348 | ||
| PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay, IC50 = 0.011 μM. | 20732809 | ||
| PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human PC3 cells after 72 hrs by alamar blue assay, IC50 = 0.015 μM. | 23215348 | ||
| PC3 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay, IC50 = 0.0153 μM. | 23489291 | ||
| NFF | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NFF cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay, IC50 = 0.0169 μM. | 23489291 | ||
| NFF | Cytotoxicity assay | 72 hrs | Cytotoxicity against human NFF cells after 72 hrs by alamar blue assay, IC50 = 0.017 μM. | 23215348 | ||
| A549 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human A549 cells after 72 hrs by alamar blue assay, IC50 = 0.02 μM. | 23215348 | ||
| KB | Cytotoxicity assay | 72 hrs | Cytotoxicity against human KB cells after 72 hrs by SRB assay, IC50 = 0.02 μM. | 26522953 | ||
| PC3 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human PC3 cells after 48 hrs by MTT assay, IC50 = 0.0276 μM. | 28038323 | ||
| HEK | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HEK cells after 72 hrs by alamar blue assay, IC50 = 0.031 μM. | 23215348 | ||
| HeLa | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HeLa cells assessed as inhibition of cell viability after 72 hrs by alamar blue assay, IC50 = 0.0358 μM. | 23489291 | ||
| HeLa | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HeLa cells after 72 hrs by alamar blue assay, IC50 = 0.036 μM. | 23215348 | ||
| BT549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human BT549 cells after 48 hrs by MTT assay, IC50 = 0.05472 μM. | 28038323 | ||
| DU145 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human DU145 cells after 48 hrs by MTT assay, IC50 = 0.0723 μM. | 28038323 | ||
| Leukemia cells | Antitumor assay | 48 hrs | Antitumor activity against human Leukemia cells after 48 hrs by SRB assay, GI50 = 0.1 μM. | 19006285 | ||
| Leukemia cells | Antitumor assay | 48 hrs | Antitumor activity against human Leukemia cells after 48 hrs by SRB assay, GI = 0.1 μM. | 19006285 | ||
| Colon cancer cells | Cytotoxicity assay | Cytotoxicity against human colon cancer cells, GI50 = 0.1 μM. | 18598018 | |||
| Leukemia cells | Cytotoxicity assay | Cytotoxicity against human leukemia cells, GI50 = 0.1 μM. | 18598018 | |||
| Colon cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Colon cancer cells after 48 hrs by SRB assay, GI50 = 0.1 μM. | 19006285 | ||
| Colon cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Colon cancer cells after 48 hrs by SRB assay, GI = 0.1 μM. | 19006285 | ||
| Leukemia cells | Antitumor assay | Antitumor activity against leukemia cells, GI50 = 0.1 μM. | 17559205 | |||
| Colon cancer cells | Antitumor assay | Antitumor activity against colon tumor cells, GI50 = 0.1 μM. | 17559205 | |||
| Leukemia cells | Growth inhibition assay | 48 hrs | Growth inhibition of human leukemia cells after 48 hrs, GI50 = 0.1 μM. | 20684599 | ||
| Colon cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human colon cancer cells after 48 hrs, GI50 = 0.1 μM. | 20684599 | ||
| Leukemia cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human leukemia cells after 48 hrs, GI50 = 0.1 μM. | 24747749 | ||
| Colon cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human colon cancer cells after 48 hrs, GI50 = 0.1 μM. | 24747749 | ||
| Leukemia cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human leukemia cells after 48 hrs, GI50 = 0.1 μM. | 22283430 | ||
| Colon cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human COLON cells after 48 hrs, GI50 = 0.1 μM. | 22283430 | ||
| MDA-MB-231 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human MDA-MB-231 cells after 48 hrs by MTT assay, IC50 = 0.1166 μM. | 28038323 | ||
| central nervous system cancer cells | Cytotoxicity assay | Cytotoxicity against human central nervous system cancer cells, GI50 = 0.12589 μM. | 18598018 | |||
| prostate cancer cells | Cytotoxicity assay | Cytotoxicity against human prostate cancer cells, GI50 = 0.12589 μM. | 18598018 | |||
| CNS | Antitumor assay | 48 hrs | Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay, GI50 = 0.12589 μM. | 19006285 | ||
| prostate cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay, GI50 = 0.12589 μM. | 19006285 | ||
| CNS | Antitumor assay | Antitumor activity against CNS tumor cells, GI50 = 0.12589 μM. | 17559205 | |||
| prostate cancer cells | Antitumor assay | Antitumor activity against prostate tumor cells, GI50 = 0.12589 μM. | 17559205 | |||
| CNS | Antitumor assay | 48 hrs | Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay, GI = 0.13 μM. | 19006285 | ||
| prostate cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay, GI = 0.13 μM. | 19006285 | ||
| prostate cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human prostate cancer cells after 48 hrs, GI50 = 0.13 μM. | 20684599 | ||
| CNS | Growth inhibition assay | 48 hrs | Growth inhibition of human CNS cancer cells after 48 hrs, GI50 = 0.13 μM. | 20684599 | ||
| CNS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CNS cancer cells after 48 hrs, GI50 = 0.13 μM. | 24747749 | ||
| prostate cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human prostate cancer cells after 48 hrs, GI50 = 0.13 μM. | 24747749 | ||
| prostate cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human prostate cancer cells after 48 hrs, GI50 = 0.13 μM. | 22283430 | ||
| CNS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CNS cancer cells after 48 hrs, GI50 = 0.13 μM. | 22283430 | ||
| Melanoma cells | Antitumor assay | 48 hrs | Antitumor activity against human Melanoma cells after 48 hrs by SRB assay, GI50 = 0.15849 μM. | 19006285 | ||
| Melanoma cells | Cytotoxicity assay | Cytotoxicity against human melanoma cells, GI50 = 0.15849 μM. | 18598018 | |||
| Melanoma cells | Antitumor assay | Antitumor activity against melanoma cells, GI50 = 0.15849 μM. | 17559205 | |||
| Melanoma cells | Antitumor assay | 48 hrs | Antitumor activity against human Melanoma cells after 48 hrs by SRB assay, GI = 0.16 μM. | 19006285 | ||
| Melanoma cells | Growth inhibition assay | Growth inhibition of human melanoma cells after 48 hrs, GI50 = 0.16 μM. | 20684599 | |||
| Melanoma cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human melanoma cells after 48 hrs, GI50 = 0.16 μM. | 24747749 | ||
| Melanoma cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human melanoma cells after 48 hrs, GI50 = 0.16 μM. | 22283430 | ||
| A549 | Antiproliferative assay | 48 hrs | Antiproliferative activity against human A549 cells after 48 hrs by MTT assay, IC50 = 0.1715 μM. | 28038323 | ||
| NSCLC | Antitumor assay | 48 hrs | Antitumor activity against human NSCLC cells after 48 hrs by SRB assay, GI = 0.25 μM. | 19006285 | ||
| NSCLC | Growth inhibition assay | 48 hrs | Growth inhibition of human NSCLC cells after 48 hrs, GI50 = 0.25 μM. | 20684599 | ||
| NSCLC | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NSCLC cells after 48 hrs, GI50 = 0.25 μM. | 22283430 | ||
| NSCLC | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NSCLC cells after 48 hrs, GI50 = 0.25 μM. | 24747749 | ||
| NSCLC | Antitumor assay | Antitumor activity against NSCLC cells, GI50 = 0.25119 μM. | 17559205 | |||
| NSCLC | Antitumor assay | 48 hrs | Antitumor activity against human NSCLC cells after 48 hrs by SRB assay, GI50 = 0.25119 μM. | 19006285 | ||
| Non-small cell lung carcinoma cells | Cytotoxicity assay | Cytotoxicity against human Non-small cell lung carcinoma cells, GI50 = 0.25119 μM. | 18598018 | |||
| ovarian cancer cells | Cytotoxicity assay | Cytotoxicity against human ovarian cancer cells, GI50 = 0.31623 μM. | 18598018 | |||
| renal cancer cells | Cytotoxicity assay | Cytotoxicity against human renal cancer cells, GI50 = 0.31623 μM. | 18598018 | |||
| breast cancer cells | Cytotoxicity assay | Cytotoxicity against human breast cancer cells, GI50 = 0.31623 μM. | 18598018 | |||
| ovarian cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay, GI50 = 0.31623 μM. | 19006285 | ||
| renal cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human renal cancer cells after 48 hrs by SRB assay, GI50 = 0.31623 μM. | 19006285 | ||
| breast cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Breast cancer cells after 48 hrs by SRB assay, GI50 = 0.31623 μM. | 19006285 | ||
| renal cancer cells | Antitumor assay | Antitumor activity against renal tumor cells, GI50 = 0.31623 μM. | 17559205 | |||
| ovarian cancer cells | Antitumor assay | Antitumor activity against ovarian tumor cells, GI50 = 0.31623 μM. | 17559205 | |||
| breast cancer cells | Antitumor assay | Antitumor activity against breast tumor cells, GI50 = 0.31623 μM. | 17559205 | |||
| ovarian cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay, GI = 0.32 μM. | 19006285 | ||
| renal cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human renal cancer cells after 48 hrs by SRB assay, GI = 0.32 μM. | 19006285 | ||
| breast cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Breast cancer cells after 48 hrs by SRB assay, GI = 0.32 μM. | 19006285 | ||
| renal cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human renal cancer cells after 48 hrs, GI50 = 0.32 μM. | 20684599 | ||
| breast cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human breast cancer cells after 48 hrs, GI50 = 0.32 μM. | 20684599 | ||
| ovarian cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human Ovarian cancer cells after 48 hrs, GI50 = 0.32 μM. | 20684599 | ||
| breast cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human breast cancer cells after 48 hrs, GI50 = 0.32 μM. | 24747749 | ||
| renal cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human renal cancer cells after 48 hrs, GI50 = 0.32 μM. | 24747749 | ||
| ovarian cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human ovarian cancer cells after 48 hrs, GI50 = 0.32 μM. | 24747749 | ||
| renal cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human renal cancer cells after 48 hrs, GI50 = 0.32 μM. | 22283430 | ||
| ovarian cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human ovarian cancer cells after 48 hrs, GI50 = 0.32 μM. | 22283430 | ||
| breast cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human breast cancer cells after 48 hrs, GI50 = 0.32 μM. | 22283430 | ||
| Lu1 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human Lu1 cells after 72 hrs by SRB assay, IC50 = 0.48 μM. | 26522953 | ||
| MCF7 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human MCF7 cells after 72 hrs by SRB assay, IC50 = 0.51 μM. | 26522953 | ||
| HepG2 | Cytotoxicity assay | 72 hrs | Cytotoxicity against human HepG2 cells after 72 hrs by SRB assay, IC50 = 0.69 μM. | 26522953 | ||
| COLON | Growth inhibition assay | 48 hrs | Growth inhibition of human colon cancer cells after 48 hrs, TGI = 3.98 μM. | 20684599 | ||
| COLON | Cytotoxicity assay | 48 hrs | Cytotoxicity against human colon cancer cells after 48 hrs, TGI = 3.98 μM. | 24747749 | ||
| COLON | Cytotoxicity assay | 48 hrs | Cytotoxicity against human COLON cells after 48 hrs, TGI = 3.98 μM. | 22283430 | ||
| COLON | Cytotoxicity assay | Cytotoxicity against human colon cancer cells, TGI = 3.98107 μM. | 18598018 | |||
| COLON | Antitumor assay | 48 hrs | Antitumor activity against human Colon cancer cells after 48 hrs by SRB assay, TGI = 3.98107 μM. | 19006285 | ||
| COLON | Antitumor assay | Antitumor activity against colon tumor cells, TGI = 3.98107 μM. | 17559205 | |||
| central nervous system cancer cells | Cytotoxicity assay | Cytotoxicity against human central nervous system cancer cells, TGI = 6.30957 μM. | 18598018 | |||
| prostate cancer cells | Cytotoxicity assay | Cytotoxicity against human prostate cancer cells, TGI = 6.30957 μM. | 18598018 | |||
| CNS | Antitumor assay | 48 hrs | Antitumor activity against human CNS cancer cells after 48 hrs by SRB assay, TGI = 6.30957 μM. | 19006285 | ||
| prostate cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human prostate cancer cells after 48 hrs by SRB assay, TGI = 6.30957 μM. | 19006285 | ||
| CNS | Antitumor assay | Antitumor activity against CNS tumor cells, TGI = 6.30957 μM. | 17559205 | |||
| prostate cancer cells | Antitumor assay | Antitumor activity against prostate tumor cells, TGI = 6.30957 μM. | 17559205 | |||
| prostate cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human prostate cancer cells after 48 hrs, TGI = 6.31 μM. | 20684599 | ||
| CNS | Growth inhibition assay | 48 hrs | Growth inhibition of human CNS cancer cells after 48 hrs, TGI = 6.31 μM. | 20684599 | ||
| CNS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CNS cancer cells after 48 hrs, TGI = 6.31 μM. | 24747749 | ||
| prostate cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human prostate cancer cells after 48 hrs, TGI = 6.31 μM. | 24747749 | ||
| prostate cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human prostate cancer cells after 48 hrs, TGI = 6.31 μM. | 22283430 | ||
| CNS | Cytotoxicity assay | 48 hrs | Cytotoxicity against human CNS cancer cells after 48 hrs, TGI = 6.31 μM. | 22283430 | ||
| Melanoma cells | Growth inhibition assay | 48 hrs | Growth inhibition of human melanoma cells after 48 hrs, TGI = 7.94 μM. | 20684599 | ||
| breast cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human breast cancer cells after 48 hrs, TGI = 7.94 μM. | 20684599 | ||
| breast cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human breast cancer cells after 48 hrs, TGI = 7.94 μM. | 24747749 | ||
| Melanoma cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human melanoma cells after 48 hrs, TGI = 7.94 μM. | 24747749 | ||
| Melanoma cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human melanoma cells after 48 hrs, TGI = 7.94 μM. | 22283430 | ||
| breast cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human breast cancer cells after 48 hrs, TGI = 7.94 μM. | 22283430 | ||
| Melanoma cells | Antitumor assay | 48 hrs | Antitumor activity against human Melanoma cells after 48 hrs by SRB assay, TGI = 7.94328 μM. | 19006285 | ||
| Melanoma cells | Cytotoxicity assay | Cytotoxicity against human melanoma cells, TGI = 7.94328 μM. | 18598018 | |||
| breast cancer cells | Cytotoxicity assay | Cytotoxicity against human breast cancer cells, TGI = 7.94328 μM. | 18598018 | |||
| breast cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human Breast cancer cells after 48 hrs by SRB assay, TGI = 7.94328 μM. | 19006285 | ||
| Melanoma cells | Antitumor assay | Antitumor activity against melanoma cells, TGI = 7.94328 μM. | 17559205 | |||
| breast tumor cells | Antitumor assay | Antitumor activity against breast tumor cells, TGI = 7.94328 μM. | 17559205 | |||
| NSCLC | Antitumor assay | Antitumor activity against NSCLC cells, TGI = 15.8489 μM. | 17559205 | |||
| Leukemia cells | Antitumor assay | 48 hrs | Antitumor activity against human Leukemia cells after 48 hrs by SRB assay, TGI = 15.8489 μM. | 19006285 | ||
| NSCLC | Antitumor assay | 48 hrs | Antitumor activity against human NSCLC cells after 48 hrs by SRB assay, TGI = 15.8489 μM. | 19006285 | ||
| Non-small cell lung carcinoma cells | Cytotoxicity assay | Cytotoxicity against human Non-small cell lung carcinoma cells, TGI = 15.8489 μM. | 18598018 | |||
| Leukemia cells | Cytotoxicity assay | Cytotoxicity against human leukemia cells, TGI = 15.8489 μM. | 18598018 | |||
| Leukemia cells | Antitumor assay | Antitumor activity against leukemia cells, TGI = 15.8489 μM. | 17559205 | |||
| NSCLC | Growth inhibition assay | 48 hrs | Growth inhibition of human NSCLC cells after 48 hrs, TGI = 15.85 μM. | 20684599 | ||
| Leukemia cells | Growth inhibition assay | 48 hrs | Growth inhibition of human leukemia cells after 48 hrs, TGI = 15.85 μM. | 20684599 | ||
| NSCLC | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NSCLC cells after 48 hrs, TGI = 15.85 μM. | 22283430 | ||
| Leukemia cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human leukemia cells after 48 hrs, TGI = 15.85 μM. | 24747749 | ||
| NSCLC | Cytotoxicity assay | 48 hrs | Cytotoxicity against human NSCLC cells after 48 hrs, TGI = 15.85 μM. | 24747749 | ||
| Leukemia cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human leukemia cells after 48 hrs, TGI = 15.85 μM. | 22283430 | ||
| renal cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human renal cancer cells after 48 hrs, TGI = 19.95 μM. | 20684599 | ||
| ovarian cancer cells | Growth inhibition assay | 48 hrs | Growth inhibition of human Ovarian cancer cells after 48 hrs, TGI = 19.95 μM. | 20684599 | ||
| renal cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human renal cancer cells after 48 hrs, TGI = 19.95 μM. | 24747749 | ||
| ovarian cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human ovarian cancer cells after 48 hrs, TGI = 19.95 μM. | 24747749 | ||
| renal cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human renal cancer cells after 48 hrs, TGI = 19.95 μM. | 22283430 | ||
| ovarian cancer cells | Cytotoxicity assay | 48 hrs | Cytotoxicity against human ovarian cancer cells after 48 hrs, TGI = 19.95 μM. | 22283430 | ||
| ovarian cancer cells | Cytotoxicity assay | Cytotoxicity against human ovarian cancer cells, TGI = 19.9526 μM. | 18598018 | |||
| renal cancer cells | Cytotoxicity assay | Cytotoxicity against human renal cancer cells, TGI = 19.9526 μM. | 18598018 | |||
| ovarian cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human ovarian cancer cells after 48 hrs by SRB assay, TGI = 19.9526 μM. | 19006285 | ||
| renal cancer cells | Antitumor assay | 48 hrs | Antitumor activity against human renal cancer cells after 48 hrs by SRB assay, TGI = 19.9526 μM. | 19006285 | ||
| renal tumor cells | Antitumor assay | Antitumor activity against renal tumor cells, TGI = 19.9526 μM. | 17559205 | |||
| ovarian tumor cells | Antitumor assay | Antitumor activity against ovarian tumor cells, TGI = 19.9526 μM. | 17559205 | |||
| PC3 | Cytotoxicity assay | 48 hrs | Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay, IC50 = 28.11 μM. | 29174816 | ||
| neural precursor cells | Function assay | Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay | 17417631 | |||
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 100 mg/mL
(108.33 mM)
Water : 100 mg/mL Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 923.04 | Formula | C46H58N4O14S |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 2068-78-2 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Leurocristine sulfate, NSC-67574 sulfate, 22-Oxovincaleukoblastine sulfate | Smiles | CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O.OS(=O)(=O)O | ||
| Targets/IC50/Ki |
Microtubules
(Cell-free assay) 32 μM
|
|---|---|
| In vitro |
Vincristine sulfate inhibits net addition of tubulin dimers at assembly ends of steady-state microtubules with Ki of 85 nM. At low concentrations, this compound stabilizes the spindle apparatus resulting in failure of the chromosomes to segregate leading to metaphase arrest and inhibition of mitosis. At higher concentrations, it may disrupt and induce total depolymerization of microtubules. This chemical induces apoptosis in tumor cells and inhibits SH-SY5Y cell proliferation with IC50 of 0.1 μM. It induces mitotic arrest and promots the expression of caspase-3 and -9 and cyclin B, while decreasing the expression of cyclin D. Its induced neurotoxicity is caused by interference with microtubule function, which results in blockage of axonal transport and thus in axonal degeneration.
|
| In vivo |
Vincristine sulfate (3 mg/kg) administrated by a single i.p. injection to mice bearing bilateral subcutaneous xenografts Rh12 or Rh18, induces mean growth delay of >120 and >52 day, and repopulating fractions of 0.06% and 5%, respectively. This compound acts on subcutaneous colon 38 tumors in mice by host cell-mediated vascular effects as well as by direct tubulin-mediated cytotoxicity. It (5 mg/kg) reduces tumor blood flow of tumors by nearly 75% .
|
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | MPM2 / Cyclin B1 / Cdc25c / p-Cdc2 / Cdc2 / Aurora B / p-H3 / p-PLK1 |
|
26156322 |
| Growth inhibition assay | Cell viability |
|
26156322 |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT05844670 | Recruiting | Pediatric Cancer |
Moi University|Princess Maxima Center for Pediatric Oncology|Amsterdam UMC location VUmc |
April 20 2023 | Phase 4 |
| NCT04448834 | Withdrawn | B-cell Acute Lymphoblastic Leukemia |
Dorothy Sipkins MD PhD|Amgen|Acrotech Biopharma Inc.|Duke University |
January 2022 | Phase 2 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.
Question 1:
I want to use it for mouse in vivo, could you please give us your advice about administration method?
Answer:
According to the reference cited on our website, we test its solubility in 4% DMSO/saline, and it is a suspension at 5 mg/mL. This compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.